NCT00661544 · ADVERSE EVENTS

Adverse events

Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients · Source last updated 2013-03-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 3 years and 1 month
Other-event reporting threshold: 5%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Arsenic Trioxide + Vitamin C + Melphalan Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)	0 / 48	0 / 48	Not reported / Not reported

Group identifiers: EG000: Arsenic Trioxide + Vitamin C + Melphalan

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

description
Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)
id
EG000
other Num Affected
0
other Num At Risk
48
serious Num Affected
0
serious Num At Risk
48
title
Arsenic Trioxide + Vitamin C + Melphalan

frequency Threshold

time Frame

3 years and 1 month

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice